Personalised molecularly matched therapies for carcinomas of unknown primary

Dr Jacob Adashek speaks to ecancer in an online interview for the virtual ESMO 2020 meeting about personalised molecularly matched therapies for carcinomas of unknown primary (CUP).

He explains that patients with CUP currently have a poor prognosis due to the rarity of the diagnosis, so the research aimed to take advantage of next-generation sequencing techniques to improve the outcomes of these patients.

Dr Adashek reports that their methods resulted in improved outcomes and discusses the potential impact of these findings beyond the treatment of CUP.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

• Categoria